CANBRIDGE PHARM.DL-00001 (MF1) - Total Liabilities
Based on the latest financial reports, CANBRIDGE PHARM.DL-00001 (MF1) has total liabilities worth €507.15 Million EUR (≈ $592.91 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore MF1 cash flow conversion to assess how effectively this company generates cash.
CANBRIDGE PHARM.DL-00001 - Total Liabilities Trend (2021–2025)
This chart illustrates how CANBRIDGE PHARM.DL-00001's total liabilities have evolved over time, based on quarterly financial data. See CANBRIDGE PHARM.DL-00001 book value and equity for net asset value and shareholders' equity analysis.
CANBRIDGE PHARM.DL-00001 Competitors by Total Liabilities
The table below lists competitors of CANBRIDGE PHARM.DL-00001 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jindal Poly Investment and Finance Company Limited
NSE:JPOLYINVST
|
India | Rs416.70 Million |
|
Pang Rim Spinn
KO:003610
|
Korea | ₩71.68 Billion |
|
John Hancock Investors Closed Fund
NYSE:JHI
|
USA | $90.58 Million |
|
Shanghai Diesel Engine Co Ltd B
SHG:900920
|
China | $9.78 Billion |
|
SkyWorld Development Berhad
KLSE:5315
|
Malaysia | RM999.57 Million |
|
FCR Immobilien AG
XETRA:FC9
|
Germany | €277.95 Million |
|
Singular People S.A.
MC:SNG
|
Spain | €43.61 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down CANBRIDGE PHARM.DL-00001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MF1 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CANBRIDGE PHARM.DL-00001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CANBRIDGE PHARM.DL-00001 (2021–2025)
The table below shows the annual total liabilities of CANBRIDGE PHARM.DL-00001 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €507.15 Million ≈ $592.91 Million |
-14.23% |
| 2024-12-31 | €591.30 Million ≈ $691.29 Million |
+35.88% |
| 2023-12-31 | €435.15 Million ≈ $508.74 Million |
+10.59% |
| 2022-12-31 | €393.49 Million ≈ $460.03 Million |
+97.60% |
| 2021-12-31 | €199.13 Million ≈ $232.81 Million |
-- |
About CANBRIDGE PHARM.DL-00001
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatme… Read more